Rifaximin in the treatment of Crohn´s disease. Results of the GRACE 02 study
IBDČes a Slov Gastroent a Hepatol 2010; 64(3): 31-36.
Summarypdf Dana Ďuricová, Martin Bortlík, Milan LukášThe role of ultrasound in diagnostics of bowel disease
Current overviewČes a Slov Gastroent a Hepatol 2010; 64(4): 18-24.
Summarypdf Daniel Bartušek, Markéta Vavříková, Vlastimil Válek, Jakub HustýEosinophilic gastroenteritis as a rare cause of ascites
Case reportČes a Slov Gastroent a Hepatol 2010; 64(4): 6-9.
Summarypdf Ivana Mikoviny Kajzrlíková, Jaroslav Štěrba, Vladimír Jr. Hořava, Josef Chalupa, Petr VítekComparative analysis of the results of laparoscopic and traditional cholecystectomy in the patients with acute cholecystitis
Original articleČes a Slov Gastroent a Hepatol 2010; 64(5): 10-14.
Summarypdf Bakhtier Nadjiyullaevich ShamirzaevPlace of sorafenib in the treatment of hepatocellular carcinoma
Current overviewČes a Slov Gastroent a Hepatol 2010; 64(5): 15-21.
Summarypdf Petra TesařováGastrointestinal Stromal Tumour: Cause of Obscure Gastrointestinal Bleeding
Case reportČes a Slov Gastroent a Hepatol 2010; 64(5): 22-25.
Summarypdf Harris Abdullah Ngow, Wan Mohd Nowalid Wan KhairinaThe efficacy of maintenance therapy in ulcerative colitis is influenced by the pharmacokinetics of mesalazine and by adherence to medicamentous therapy Commentary to the PODIUM study
IBDČes a Slov Gastroent a Hepatol 2010; 64(5): 26-29.
Summarypdf Milan LukášBiodegradable stents in benign stenosis of the biliary tract
EndocsopyČes a Slov Gastroent a Hepatol 2010; 64(6): 31-34.
Summarypdf Jan Hajer, Zdena Zádorová, Eva PlíškováWhat should be done in patients with inflammatory bowel diseases those lose a response to biological therapy?
Review articleGastroent Hepatol 2011; 65(1): 36-39.
Summarypdf Milan LukášIs it possible to reintroduce original biological therapy in a relapsed Crohn
Case reportGastroent Hepatol 2011; 65(1): 33-35.
Summarypdf Tomáš Zamborský, Barbora Desatová, Marián Bátovský, Igor Páv